Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk

Stevens KN, Garcia-Closas M, Fredericksen Z, Kosel M, Pankratz VS, Hopper JL, Dite GS, Apicella C, Southey MC, Schmidt MK, Broeks A, Van 'T Veer LJ, Tollenaar RAEM, Fasching PA, Beckmann M, Hein A, Ekici AB, Johnson N, Peto J, Silva IDS, Gibson L, Sawyer E, Tomlinson I, Kerin MJ, Chanock S, Lissowska J, Hunter DJ, Hoover RN, Thomas GD, Milne RL, Perez JIA, Gonzalez-Neira A, Benitez J, Burwinkel B, Meindl A, Schmutzler RK, Bartrar CR, Hamann U, Ko YD, Bruening T, Chang-Claude J, Hein R, Wang-Gohrke S, Doerk T, Schuermann P, Bremer M, Hillemanns P, Bogdanova NV, Zalutsky JV, Rogov YI, Antonenkova N, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Chenevix-Trench G, Chen X, Peterlongo P, Bonanni B, Bernard L, Manoukian S, Wang X, Cerhan J, Vachon CM, Olson J, Giles GG, Baglietto L, Mclean CA, Severi G, John EM, Miron A, Winqvist R, Pylkaes K, Jukkola-Vuorinen A, Grip M, Andrulis IL, Knight JA, Glendon G, Mulligan AM, Cox A, Brock IW, Elliott G, Cross SS, Pharoah PP, Dunning AM, Pooley KA, Humphreys MK, Wang J, Kang D, Yoo KY, Noh DY, Sangrajrang S, Gabrieau V, Brennan P, Mckay J, Anton-Culver H, Ziogas A, Couch FJ, Easton DF (2011)

Publication Type: Journal article

Publication year: 2011

Journal

Book Volume: 105

Pages Range: 1934-1939

Journal Issue: 12

DOI: 10.1038/bjc.2011.448

Abstract

Background: Somatic mutations in phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) are frequent in breast tumours and have been associated with oestrogen receptor (ER) expression, human epidermal growth factor receptor-2 overexpression, lymph node metastasis and poor survival. The goal of this study was to evaluate the association between inherited variation in this oncogene and risk of breast cancer. Methods: A single-nucleotide polymorphism from the PIK3CA locus that was associated with breast cancer in a study of Caucasian breast cancer cases and controls from the Mayo Clinic (MCBCS) was genotyped in 5436 cases and 5280 controls from the Cancer Genetic Markers of Susceptibility (CGEMS) study and in 30 949 cases and 29 788 controls from the Breast Cancer Association Consortium (BCAC). Results: Rs1607237 was significantly associated with a decreased risk of breast cancer in MCBCS, CGEMS and all studies of white Europeans combined (odds ratio (OR)=0.97, 95% confidence interval (CI) 0.95-0.99, P=4.6 × 10 3), but did not reach significance in the BCAC replication study alone (OR=0.98, 95% CI 0.96-1.01, P=0.139).Conclusion: Common germline variation in PIK3CA does not have a strong influence on the risk of breast cancer. © 2011 Cancer Research UK All rights reserved.

Authors with CRIS profile

Involved external institutions

University of California Los Angeles (UCLA) United States (USA) (US) National Cancer Institute (NCI) United States (USA) (US) Mayo Clinic United States (USA) (US) The Institute of Cancer Research (ICR) United Kingdom (GB) The University of Melbourne Australia (AU) Netherlands Cancer Institute (NKI) Netherlands (NL) Leiden University Netherlands (NL) University College London (UCL) United Kingdom (GB) London School of Hygiene and Tropical Medicine United Kingdom (GB) King’s College London United Kingdom (GB) University of Oxford United Kingdom (GB) National University of Ireland (NUI), Galway Ireland (IE) Maria Skłodowska-Curie Institute of Oncology / Centrum Onkologii–Instytut im. Marii Skłodowskiej-Curie w Warszawie Poland (PL) Harvard University United States (USA) (US) Spanish National Cancer Research Centre / Centro Nacional de Investigaciones Oncológicas (CNIO) Spain (ES) Hospital Monte Naranco Spain (ES) Universitätsklinikum Heidelberg Germany (DE) Technische Universität München (TUM) Germany (DE) Universitätsklinikum Köln Germany (DE) Ruprecht-Karls-Universität Heidelberg Germany (DE) Deutsches Krebsforschungszentrum (DKFZ) Germany (DE) Evangelische Kliniken Bonn gGmbH Germany (DE) Institut für Prävention und Arbeitsmedizin der Deutschen Gesetzlichen Unfallversicherung (IPA) Germany (DE) Universität Ulm Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School Germany (DE) Karolinska Institute Sweden (SE) University of Eastern Finland Finland (FI) QIMR Berghofer Medical Research Institute (früher: the Queensland Institute of Medical Research) Australia (AU) Fondazione IRCCS: Istituto Nazionale dei Tumori Italy (IT) European Institute of Oncology / Istituto Europeo di Oncologia (IEO) Italy (IT) The Alfred Hospital Australia (AU) Cancer Prevention Institute of California (CPIC) United States (USA) (US) Dana–Farber Cancer Institute United States (USA) (US) Oulun Yliopisto / University of Oulo Finland (FI) Ontario Cancer Genetics Network Canada (CA) Mount Sinai Hospital (MSH) Canada (CA) University of Toronto Canada (CA) University of Sheffield United Kingdom (GB) University of Manchester United Kingdom (GB) University of Cambridge United Kingdom (GB) Seoul National University (SNU) / 서울대학교 Korea, Republic of (KR) International Agency for Research on Cancer (IARC) France (FR) University of California Irvine United States (USA) (US)

How to cite

APA:

Stevens, K.N., Garcia-Closas, M., Fredericksen, Z., Kosel, M., Pankratz, V.S., Hopper, J.L.,... Easton, D.F. (2011). Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk. British Journal of Cancer, 105(12), 1934-1939. https://doi.org/10.1038/bjc.2011.448

MLA:

Stevens, K. N., et al. "Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk." British Journal of Cancer 105.12 (2011): 1934-1939.

BibTeX: Download